SANDOZ CEFTRIAXONE POWDER FOR SOLUTION

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Prieinama:

SANDOZ CANADA INCORPORATED

ATC kodas:

J01DD04

INN (Tarptautinis Pavadinimas):

CEFTRIAXONE

Dozė:

1G

Vaisto forma:

POWDER FOR SOLUTION

Sudėtis:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 1G

Vartojimo būdas:

INTRAMUSCULAR

Vienetai pakuotėje:

100

Recepto tipas:

Prescription

Gydymo sritis:

THIRD GENERATION CEPHALOSPORINS

Produkto santrauka:

Active ingredient group (AIG) number: 0117292003; AHFS:

Autorizacija statusas:

CANCELLED PRE MARKET

Leidimo data:

2018-08-01

Prekės savybės

_ _
PRODUCT MONOGRAPH
SANDOZ CEFTRIAXONE
Sterile Ceftriaxone for Injection BP
1 G AND 2 G CEFTRIAXONE PER VIAL (INCORPORATED AS CEFTRIAXONE SODIUM)
ANTIBIOTIC
Sandoz Canada Inc.
Date of Revision: January 15, 2010
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
CONTROL # : 133307
_Sandoz Ceftriaxone _
_ Page 2 of 51_
_ _
TABLE OF CONTENTS
HEALTH PROFESSIONAL
INFORMATION.........................................................................
3
ACTION
.....................................................................................................................................
3
INDICATIONS AND CLINICAL
USES...................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS...............................................................................................................................
4
PRECAUTIONS.........................................................................................................................
6
ADVERSE
REACTIONS...........................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
....................................................... 10
DOSAGE AND
ADMINISTRATION.....................................................................................
10
ADMINISTRATION................................................................................................................
11
PHARMACEUTICAL
INFORMATION.................................................................................
13
DRUG
SUBSTANCE...............................................................................................................
13
DRUG
PRODUCT....................................................................................................................
13
RECONSTITUTION
.......................................................................................